首页> 外文期刊>Clinical Pharmacology and Therapeutics >Effects of Palonosetron on Perioperative Cardiovascular Complications in Patients Undergoing Noncardiac Surgery With General Anesthesia: A Retrospective Cohort Study
【24h】

Effects of Palonosetron on Perioperative Cardiovascular Complications in Patients Undergoing Noncardiac Surgery With General Anesthesia: A Retrospective Cohort Study

机译:帕洛诺司琼对全麻非心脏手术患者围手术期心血管并发症的影响:一项回顾性队列研究

获取原文
获取原文并翻译 | 示例
           

摘要

We retrospectively investigated whether palonosetron administered during the induction of general anesthesia is associated with an increased risk of perioperative cardiovascular complications in a single tertiary center cohort consisting of 4,517 palonosetron-exposed patients and 4,517 propensity score-matched patients without palonosetron exposure. The primary endpoint was a composite of perioperative cardiovascular complications, including intraoperative cardiac arrhythmia, intraoperative cardiac death, and myocardial injury within the first postoperative week, and there was no significant difference between the groups (odds ratio [OR] = 1.04; 95% confidence interval [Cl] = 0.92-1.19). As secondary endpoints, intraoperative cardioversion, cardiac compression, use of cardiovascular drugs, postoperative hospital stay, and in-hospital mortality showed no differences between the groups. However, the palonosetron group showed decreased intraoperative hypotension (OR = 0.88; 95% Cl = 0.79-0.97) and length of postoperative intensive care unit (ICU) stay (4.26 ± 9.86 vs. 6.14 ± 16.75; P = 0.026). Palonosetron did not increase the rate of perioperative cardiovascular complications, and can therefore be used safely during anesthetic induction.
机译:我们回顾性研究了在全麻诱导期间施用帕洛诺司琼是否与单次三中心研究队列中围手术期心血管并发症的风险增加相关,该队列由4,517名接受帕洛诺司琼暴露的患者和4,517例倾向评分匹配的患者组成,未接受帕洛诺司琼暴露。主要终点是围手术期心血管并发症的综合因素,包括术中心律失常,术中心脏死亡和术后一周内的心肌损伤,两组之间无显着差异(优势比[OR] = 1.04; 95%置信度区间[Cl] = 0.92-1.19)。作为次要终点,术中心脏复律,心脏压迫,使用心血管药物,术后住院时间和院内死亡率在两组之间无差异。然而,帕洛诺司琼组显示术中低血压降低(OR = 0.88; 95%Cl = 0.79-0.97),术后重症监护病房(ICU)停留时间长(4.26±9.86 vs. 6.14±16.75; P = 0.026)。帕洛诺司琼没有增加围手术期心血管并发症的发生率,因此可以在麻醉诱导期间安全使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号